by @dministrator | Oct 11, 2023 | Vyluma
— Prescription Drug User Fee Act (PDUFA) goal date of January 31, 2024 — Bridgewater, NJ – October 11, 2023 – Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets for the treatment of refractive errors, announced today positive top-line...
by @dministrator | Jun 6, 2023 | Vyluma
Bridgewater, NJ – June 6, 2023 – Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets for the treatment of refractive errors, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application...
by @dministrator | Jan 5, 2023 | Vyluma
Bridgewater, NJ – January 5, 2023 – Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets for the treatment of refractive errors, today announced it will present at the 41st annual J.P. Morgan Healthcare Conference, taking place January 9-12,...
by @dministrator | Oct 27, 2022 | Vyluma
Preliminary data from landmark, three-year, international study demonstrate safety and efficacy of NVK002 as a potential treatment for the progression of myopia in children Bridgewater, NJ – October 27, 2022 – Vyluma, Inc (“Vyluma”), a biopharmaceutical...
by @dministrator | Sep 1, 2022 | Vyluma
Multi-center, international clinical study designed to assess the safety and efficacy of novel investigational low-dose atropine eye drops in children 3-17 years old with myopia Bridgewater, NJ – September 1, 2022 – Vyluma, Inc. (“Vyluma”), a biopharmaceutical company...
by @dministrator | Jun 14, 2022 | Vyluma
Bridgewater, NJ, USA, June 14, 2022 – Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets in the ophthalmic space for the treatment of refractive errors, and Laboratoires Théa (“Théa”) announced that they have recently entered into an...
Recent Comments